Concordance between the diagnostic guidelines for alcohol and cannabis use disorders in the draft ICD‐11 and other classification systems: analysis of data from the WHO's World Mental Health Surveys

Background and aims The World Health Organization's (WHO's) proposed International Classification of Diseases, 11th edition (ICD‐11) includes several major revisions to substance use disorder (SUD) diagnoses. It is essential to ensure the consistency of within‐subject diagnostic findings t...

Full description

Saved in:
Bibliographic Details
Published inAddiction (Abingdon, England) Vol. 114; no. 3; pp. 534 - 552
Main Authors Degenhardt, Louisa, Bharat, Chrianna, Bruno, Raimondo, Glantz, Meyer D., Sampson, Nancy A., Lago, Luise, Aguilar‐Gaxiola, Sergio, Alonso, Jordi, Andrade, Laura Helena, Bunting, Brendan, Caldas‐de‐Almeida, Jose Miguel, Cia, Alfredo H., Gureje, Oye, Karam, Elie G., Khalaf, Mohammad, McGrath, John J., Moskalewicz, Jacek, Lee, Sing, Mneimneh, Zeina, Navarro‐Mateu, Fernando, Sasu, Carmen C., Scott, Kate, Torres, Yolanda, Poznyak, Vladimir, Chatterji, Somnath, Kessler, Ronald C.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.03.2019
Subjects
Online AccessGet full text
ISSN0965-2140
1360-0443
1360-0443
DOI10.1111/add.14482

Cover

More Information
Summary:Background and aims The World Health Organization's (WHO's) proposed International Classification of Diseases, 11th edition (ICD‐11) includes several major revisions to substance use disorder (SUD) diagnoses. It is essential to ensure the consistency of within‐subject diagnostic findings throughout countries, languages and cultures. To date, agreement analyses between different SUD diagnostic systems have largely been based in high‐income countries and clinical samples rather than general population samples. We aimed to evaluate the prevalence of, and concordance between diagnoses using the ICD‐11, The WHO's ICD 10th edition (ICD‐10) and the Diagnostic and Statistical Manual of Mental Disorders, 4th and 5th editions (DSM‐IV, DSM‐5); the prevalence of disaggregated ICD‐10 and ICD‐11 symptoms; and variation in clinical features across diagnostic groups. Design Cross‐sectional household surveys. Setting Representative surveys of the general population in 10 countries (Argentina, Australia, Brazil, Colombia, Iraq, Northern Ireland, Poland, Portugal, Romania and Spain) of the World Mental Health Survey Initiative. Participants Questions about SUDs were asked of 12 182 regular alcohol users and 1788 cannabis users. Measurements Each survey used the World Mental Health Survey Initiative version of the WHO Composite International Diagnostic Interview version 3.0 (WMH‐CIDI). Findings Among regular alcohol users, prevalence (95% confidence interval) of life‐time ICD‐11 alcohol harmful use and dependence were 21.6% (20.5–22.6%) and 7.0% (6.4–7.7%), respectively. Among cannabis users, 9.3% (7.4–11.1%) met criteria for ICD‐11 harmful use and 3.2% (2.3–4.0%) for dependence. For both substances, all comparisons of ICD‐11 with ICD‐10 and DSM‐IV showed excellent concordance (all κ ≥ 0.9). Concordance between ICD‐11 and DSM‐5 ranged from good (for SUD and comparisons of dependence and severe SUD) to poor (for comparisons of harmful use and mild SUD). Very low endorsement rates were observed for new ICD‐11 feature for harmful use (‘harm to others’). Minimal variation in clinical features was observed across diagnostic systems. Conclusions The World Health Organization's proposed International Classification of Diseases, 11th edition (ICD‐11) classifications for substance use disorder diagnoses are highly consistent with the ICD 10th edition and the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM‐IV). Concordance between ICD‐11 and the DSM 5th edition (DSM‐5) varies, due largely to low levels of agreement for the ICD harmful use and DSM‐5 mild use disorder. Diagnostic validity of self‐reported ‘harm to others’ is questionable.
Bibliography:Core group.
A complete list of all within‐country and cross‐national WMH publications can be found at
The WHO World Mental Health Survey collaborators are: Sergio Aguilar‐Gaxiola MD, PhD, Ali Al‐Hamzawi MD, Mohammed Salih Al‐Kaisy MD, Jordi Alonso MD, PhD, Laura Helena Andrade MD, PhD, Corina Benjet PhD, Guilherme Borges ScD, Evelyn J. Bromet PhD, Ronny Bruffaerts PhD, Brendan Bunting PhD, Jose Miguel Caldas de Almeida MD, PhD, Graça Cardoso MD, PhD, Somnath Chatterji MD, Alfredo H. Cia MD, Louisa Degenhardt PhD, Koen Demyttenaere MD, PhD, John Fayyad MD, Silvia Florescu MD, PhD, Giovanni de Girolamo MD, Oye Gureje MD, DSc, FRCPsych, Josep Maria Haro MD, PhD, Yanling He MD, Hristo Hinkov MD, PhD, Chi‐yi Hu MD, PhD, Yueqin Huang MD, MPH, PhD, Peter de Jonge PhD, Aimee Nasser Karam PhD, Elie G. Karam MD, Norito Kawakami MD, DMSc, Ronald C. Kessler PhD, Andrzej Kiejna MD, PhD, Viviane Kovess‐Masfety MD, PhD, Sing Lee MB, BS, Jean‐Pierre Lepine MD, Daphna Levinson PhD, John McGrath MD, PhD, Maria Elena Medina‐Mora PhD, Zeina Mneimneh PhD, Jacek Moskalewicz PhD, Fernando Navarro‐Mateu MD, PhD, Beth‐Ellen Pennell MA, Marina Piazza MPH, ScD, Jose Posada‐Villa MD, Kate M. Scott PhD, Tim Slade PhD, Juan Carlos Stagnaro MD, PhD, Dan J. Stein FRCPC, PhD, Margreet ten Have PhD, Yolanda Torres MPH, Dra. HC, Maria Carmen Viana MD, PhD, Harvey Whiteford MBBS, PhD, David R. Williams MPH, PhD and Bogdan Wojtyniak ScD.
http://www.hcp.med.harvard.edu/wmh/
.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
The WHO World Mental Health Survey collaborators are Sergio Aguilar-Gaxiola, MD, PhD, Ali Al-Hamzawi, MD, Mohammed Salih Al-Kaisy, MD, Jordi Alonso, MD, PhD, Laura Helena Andrade, MD, PhD, Corina Benjet, PhD, Guilherme Borges, ScD, Evelyn J. Bromet, PhD, Ronny Bruffaerts, PhD, Brendan Bunting, PhD, Jose Miguel Caldas de Almeida, MD, PhD, Graça Cardoso, MD, PhD, Somnath Chatterji, MD, Alfredo H. Cia, MD, Louisa Degenhardt, PhD, Koen Demyttenaere, MD, PhD, John Fayyad, MD, Silvia Florescu, MD, PhD, Giovanni de Girolamo, MD, Oye Gureje, MD, DSc, FRCPsych, Josep Maria Haro, MD, PhD, Yanling He, MD, Hristo Hinkov, MD, PhD, Chi-yi Hu, MD, PhD, Yueqin Huang, MD, MPH, PhD, Peter de Jonge, PhD, Aimee Nasser Karam, PhD, Elie G. Karam, MD, Norito Kawakami, MD, DMSc, Ronald C. Kessler, PhD, Andrzej Kiejna, MD, PhD, Viviane Kovess-Masfety, MD, PhD, Sing Lee, MB, BS, Jean-Pierre Lepine, MD, Daphna Levinson, PhD, John McGrath, MD, PhD, Maria Elena Medina-Mora, PhD, Zeina Mneimneh, PhD, Jacek Moskalewicz, PhD, Fernando Navarro-Mateu, MD, PhD, Beth-Ellen Pennell, MA, Marina Piazza, MPH, ScD, Jose Posada-Villa, MD, Kate M. Scott, PhD, Tim Slade, PhD, Juan Carlos Stagnaro, MD, PhD, Dan J. Stein, FRCPC, PhD, Margreet ten Have, PhD, Yolanda Torres, MPH, Dra.HC, Maria Carmen Viana, MD, PhD, Harvey Whiteford, MBBS, PhD, David R. Williams, MPH, PhD, Bogdan Wojtyniak, ScD.
ISSN:0965-2140
1360-0443
1360-0443
DOI:10.1111/add.14482